The ongoing, open-label, single-arm, pivotal phase II FIREFLY-1 clinical trial, evaluating DAY101 (tovorafenib) as once-weekly monotherapy in patients aged 6 months to 25 years with relapsed or progressive pediatric low-grade glioma, yielded positive initial data from the first 22 patients enrolled.
NXP900 yielded positive data in a preclinical xenograft model of group 4 medulloblastoma.
SomaLogic and OncoHost signed a licensing agreement, through which OncoHost will license SomaLogic’s SomaScan Platform to develop proteomics tests for its PROphet diagnostic system, designed to predict patients’ response to immunotherapy treatments and provide strategies to overcome treatment resistance.
The University of Texas MD Anderson Cancer Center, Invectys Inc., and the Cell Therapy Manufacturing Center, a joint venture between MD Anderson and National Resilience Inc., announced a strategic collaboration to jointly develop a process for human leukocyte antigen-G targeted CAR T-cell therapy for solid tumors.
The plenary session at the ASCO 2022 annual meeting saw that rarest of things at a scientific conference: a standing ovation.
All fourteen rectal cancer patients in a small phase II study of dostarlimab, an anti-PD-1 monoclonal antibody, saw their cancer completely disappear—with no progression or recurrence at follow-up six to 25 months later. None of the patients required further chemotherapy, radiation, or surgery.
NCI must make a bigger investment in new cancer therapies and expand the clinical trials system that tests them, the institute’s Acting Director Douglas Lowy said in his remarks at the American Society of Clinical Oncology annual meeting June 4.
Fadlo Khuri, president of the American University of Beirut, was honored for his service as editor-in-chief of Cancer, a journal of the American Cancer Society, in a reception June 3 at the 2022 ASCO annual meeting.
The American Association for Cancer Research released its Cancer Disparities Progress Report 2022, the second AACR report on this topic.
Darrel P. Cohen was named chief medical officer of cell therapy at Athenex Inc. In this role, Cohen will lead the company’s clinical development, clinical operations, and regulatory affairs functions, replacing Kurt Gunter.
